Futura Medical Share Chat (FUM)

"...it's taken them most of the day to hoover up the sells to fill that buy order of 92850 shares..."

No, that's just the end of day uncrossing.

Agree, it's just the spread, some days closing on the bid, other days on the ask.

All driven by a lack of liquidity, it's taken them most of the day to hoover up the sells to fill that buy order of 92850 shares @ 9.65p £8913

Hopefully it was only part filled and there is more tomorrow, but ultimately the price isn't going to move without news.

Next stop Haleon AGM statement 28th May, but I wouldn't expect anything there to be honest, and then the FUM AGM towards the end of June.

"Haven't seen a jump in SP like this since... "

Look more closely and you'll see that you haven't seen 'a jump like this' at all. But you may see a widening of the spread, which is telling...

Need to rub a 4 pack on the sp.....

Let's hope they can pump utcto 40p then

It is still the no2 bestseller in the sexual enhancers category on us amazon and one of the three most wishes for package items, as well as in the gift ideas package.

We seem to be holding steady on Amazon with roughly now

5k in sales a month (USA) without really any push in promoting.

The company seems to really not say much which in past may be a good thing as we know what happened when they did.

Ffs.

Really Rpg7, the bod are doing a cracking job of nausing this up. Look at the SP its lower now than it has been for over 5 years! We may as well not bothered developing Erexon as FUM was better off without it!

The way this share performs make no logical sense to me. I was always of the opinion anything to do with 'sex' sells. This is an over the counter product,(huge advantage ) tested with a more than fair chance of working ,for sale in a number of countries ( including the USA) as well as NHS! I suppose the negative is the witless bod, but surely even those clowns should not be able to nause it up so badly.

Is anybody any the wiser why JB announced a 50% reduction in sales for 2025 yet by his own admission has no f in idea as sales fluctuate. Still think this was done on purpose to tank the SP! Sep 24 it’s very hard to forecast sales yet has forecasted 2025?? Please remove this w anker from the company Lombard please!

At least Lombard are on the board now, wouldn’t take much to topple the board & take ownership so bod will have to perform someone on their a r s e now & SP matters! Salaries of bod needs looking at IMO with current earnings.

The value of the shares being bought and sold is pathetic in the grand scheme of things!

No news news here, but any publicity is good publicity for FUM at the mo.

https://simplywall.st/stocks/gb/retail/lse-ultp/ultimate-products-shares/news/3-uk-penny-stocks-with-market-caps-under-200m-to-watch

Futura Medical (AIM:FUM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Futura Medical plc researches, develops, and sells pharmaceutical and healthcare products for sexual health with a market cap of £30.26 million.

Operations: The company generates revenue primarily from the development and commercialization of MED3000, amounting to £13.93 million.

Market Cap: £30.26M

Futura Medical plc, with a market cap of £30.26 million, recently reported significant revenue growth to £13.93 million for 2024, marking its transition to profitability with a net income of £1.29 million compared to a previous net loss. The company's Price-To-Earnings ratio (23.4x) is below the industry average, suggesting potential value for investors. Futura Medical remains debt-free and has stable short-term assets exceeding liabilities, though it experiences higher volatility than most UK stocks. Recent board changes include the appointment of Harmesh Suniara as Non-executive Director, bringing extensive investment management experience focused on UK equities.

I think a few slime balls know why we are where we are, karma.

It's almost pointless de-ramping as the company seems successful at doing that itself.

I sold out here a couple of months ago after loosing out yet again on FUM. I keep an eye on it because I did believe this had huge potential but it never seems to achieve it.

Oddly enough the broker estimates are all buys with the S.P. forecast to be considerably higher than it currently is. One day it may just achieve these lofty expectations.

Top up ,you are an expert at inept de-ramping.

Afternoon, bucolic.fair comment as we are certainly short of optimism at the moment. can't believe LB is still going.yes mental health issues seem very likely. yes im still here, but pretty relaxed i sold out entirely first time around at about60p and only reinvested with a smaller holding for second time averaging about 40p.even if it goes bust (which i dont expect)i will still have made very significant profits overall.im pretty surprised at where we are now and clearly you were very prescient in your decision to exit, although i still think there is plenty of potential here to come out ahead again.we shalll see. all the best to you.

Hi T.I! Don't know about that - there was a lot more optimism then, and the bears were easier to slay. Are you still in here? I saw which way the wind was blowing a while back and packed my bags. Over the years I've come out slightly ahead by occasionally taking profit, but Fantasy Island is going to have to wait for another day! I've binned off ADVFN now, LiarBOoth is talking to an empty room! (Yes, he's still going, must be a mental health issue).

Think they must sit in the board room with headphones on listing to 'white noise', to drown out any spoken common sense.

I emailed both CEO and CFO and said they should resign, as they have no idea how to run a company....of course I didn't hear anything.

I also email Lombard, just after barder made that awful annoucement that they should start putting pressure on CEO and CFO to stand down.....At least Lombard are on the Non Exec board...

This is the fourth country that Navamedic have launched in. Either they are contractually obliged to do so or, based on their experience in the other 3 countries, they considered it worthwhile.

Either way, I’ve topped up my holding today. Fingers crossed that this is the bottom!

Wonder if anyone told bader ?,probably too busy counting paper clips.

Amazing how since Barder's kiss of death end of Jan, no announcement will move the price and the BOD clearly don't give a monkey's

Yeah..... u got me! It's a habit

You've peeked, haven't you?

Maybe not mentioning Eroxon sales gives Haleon more time to deliberate on an acquisition of FUM & keep the price low?? How does a product with great opening marketing in the UK / Belgium & the Nordics fail to deliver in other territories? EU is coopers fault but US what is happening??

Haleon Capital Markets Day (5hr event)

Not one single mention of Eroxon, but I don't take that as a negative. The whole event centered on their core / marquee brands (Sensodine, Centrum & Volterol) and business operation

They did say that they intend to "maintain healthy investment in A&P" (advertising & promo)

Also, "Well positioned for future bolt on M&A in strategic growth areas" Such opportunities would need to be

i) Strong strategic fit

ii) Winning player

iii) Attractive financials

iv) Synergistic value creation

(not sure that spells out Eroxon tbh)

Give up refreshin the page for this, everytime i do it goes down. So theory, no refreshie, sp goes uppie!! Week challenge. Go on FUM, for giggles, no ones lookin..... or me refreshing. Up u go, surge n soar, big open mouth emoji's

This company reminds me of the 'Producers' where the cast deliberately selected to fail, fortunately ,that had the wrong ending.

It’s like a conspiracy to keep FUM SP low, to not report on Eroxon as their first OTC ED product & new segment seems a little strange? Not sure what to make of it, expect it from FUM but Haleon playing smoke & mirrors as well?? Maybe as they say no news is good news?

It's cool man, nice to hear other doom annd gloom and not the echo chamber here. :) hodl for godl eh,

Thanks Italian...yeh im well under water and had almost give up...but nice to see that the product may at last make an appearance.....i remember when these were 7 HK dollars....did they give up on our markets for the product.....anyway a rise is always good...long way to go....sorry everyone for off topic

Hello ex sparky.yes i am. it still is a p/e company ,although it now also owns deep longevity inc,an ageing clock longevity focussed ai company. regent has recently submitted its formal application to the chinese medical authority for approval of senstend`(the chines name for fortacin)and is hoping for approval by year end(although this is probably a tad optimistic). there is also a refinancing share issue exercise going on.,after which mellon and his pet companies will own just under 70% of the company,sosvery small pi free float. no one has any idea why its shooting up, although speculation is that it is in anticipation of chinese approval, but as that is months away at best, i'm not convinces. this is a potted version.you need to read the old plethora board(its still going on here)and read the regent announcements to see the long history.this is not a buy recommendation in any sense. most long term investors are massively under water. hope this helps a bit.

Sorry for off topic but anyone here still in Regent Pacific...what was PLE.sudden rise and not sure why....was originally a PE company

The other reason is the Bod are f.ukwits

Makes no difference what people say here, as I’ve always said sales is the merit of the product, problem is sales will rise & fall as the market adapts , we are non the wiser after 24 update! My only issue is they give no update on the UK which had high sales & eventually captured 20% of the ED market after 1 year? Where is it now??? US sales are key & the Haleon Q1 update will move it either way!!!! I’m hoping upwards but stuck here currently as I do see a return eventually just wish I’d sold & bought back in! But I’m useless at that!!!

Whoops ,loud toss up your shorts are showing.

Increased 7 fold? 7 x nak all = nak all. Just saying.

The Lord

Boots had a 24hr flash sale for EROXON yesterday and sales increased 7 fold comfortably beating all the other ED products (cialisi Viagra sildefanil) several time over. Have always said the £25 box of 4 makes it too expensive for spontaneous purchases and single or doubles at £5 or £10 a pop would get things moving .

proves at the right price this product moves. Eroxon has serious well established proven competition (albeit different mechanism) so price will always be a factor

No hope, no life, it's dead jim.

Longest auction I've seen! Rns incoming?

available via research tree

no new news, no rating, no price target

https://*********************/companies/uk/pharmaceuticals/futura-medical-plc/research/trinity-delta/trinity-delta-lighthouse-futura-medical/33_b7ca5bb3-5de5-48ca-9504-c94be59205d3/8411117a-1130-4221-aa43-e490004b418d

It is impossible to form a rational opinion as to what is going on at this company. Long-standing shareholders are treated with disrespect by Barder - why is he kept on ? The share price is now near the 7p (?) placing pre-covid never mind the more recent 40p (?) one all supported by Lombard Odier.

Now they have at last shown some metal by placing their man on the Board but still we don’t get clarity as to where we as a company are going.

Is this now a buying opportunity at this low price or should we cut our losses and run ?

Also, for those interestedly would recommend listening to the investor meet (retail)presentation.you have to put up with borders downbeat style(which is not enlivened by his somewhat lugubrious appearance),but the actual content is quite interesting and certainly for me helped maintain confidence despite the recent disappointing s/p performancehttps://presentations.investormeetcompany.com/investor-meet-company/futura-medical-plc-full-year-results?bmid=1d1e2a48c930

In that context james,you will recall slock's post regarding the FY25 milestone payments (plural?) not being lost. that doesn't,of course, mean they will be achieved, but it does keep the possibility open, even if they actually fall in the following year. far too much premature negativity here imo.

Https://www.proactiveinvestors.co.uk/companies/news/1069904/futura-medical-targets-20-markets-for-eroxon-icymi-1069904.html

JtB: Trying to draw a crowd or just dig yourself out of a hole?

I remember the fund raise a few years back when the directors proudly stated they were participating with chunky purchases. On reviewing the year end accounts released a few months later, they had paid themselves bonuses which almost exactly equalled the share purchase. Maybe one day you guys will twig this is a classic AIM gravy train which pays the directors very handsomely whilst returning zilch to shareholders. Maybe one day ............

The Lord

This is now your typical AIM failure. The company has at best a year or two left (with having to refund license up front payments or failing to meet sales targets and a product with a limited market). All that will happen is a drawn out process where directors will keep it going as long as they have money to draw.

Absolutely outraeous!!! When is the AGM and can we attend?

It's not too late just yet, got enough cash H2 2026 and Haleon have only just started. Haleon manufacture, distribute, advertise so very little Barder can do to help that go wrong. They have new Brand Manager in, have innovated already with 8 pack, adapted marketing with celebrity lauch of Ed (ED) the Chat bot on the website. Already showing how professional they are.

2025 can be recovered with 8 pack in stores alongside the 4 pack. That would generate the same volume, or more than the original 4 pack launch going into stores. That may even end up triggering a milestone after all for 2025? Thats 1 year of US 4 pack sales, 2024 had 3 months at best, and 8 pack stocking in sales. Likely 4 pack stocking in payment for FUM circa £2M.

2026 Full year US sales with learnings implemented from first full year and then stocking in sales for Intense 4 pack and 8 pack if they follow original Eroxon format. 2026 will also have Intense rollout to ROW.

Eroxon Intense will likely be a better product with the sensorial benefit.

So the launch of Haleon 8 pack may turn 2025 around otherwise it's wait for Eroxon Intense and rely on Haleon professionals running things in US rather than FUM.

What happened to the time when you setup a business and took minimum salary until the business could afford a decent salary that had been earned? Too easy to setup an Aim company & too many institutional investors backing them with no curtailment of salaries! LB involved now but too late they’ve already emptied the till thieving Twats!

Exactly so why ruin a lfestyle? Only lombard significantly increasing their stake could affect that realistically. The ol' old boys club eh?

In 2020 total staff 13 costing £2m, 3 directors took home £1m! Over doubled their salaries in 5 years

He can earn all the money in the world ,but, he will always be a greedy useless to--er., who could not run a raffle.

At least one analyst following Haleon has suggested to their CEO that they do it. £40M of tax losses to utilise, save the milestones, possibly accelerate wsd4000 to market. Gain rest of the world licenses. Absorb outfourced FUM manufacturing themselves. Dismiss FUM BOD and non essential staff. Never have to deal with Barder or Hildreth again. Inttoduce 8 and 28 pack across all stores.

If Lombard increased their % to 51% costing around £6m, they could save £2m annually by removing JB & AH for gross incompetence & recover that £6m in 3 years? I feel without those two idiots the SP would increase just from removing them so may see a return even quicker!

BOD have little value now, just Ken James to keep delivery pipeline to Haleon. The real future is Haleon and their professional expertise to execute strategy now not FUM BOD. So already Haleon have an 8 pack, the stores buy that to shelf stock, which is an immediate sales boost, why didn't FUM and Coopers think of that?

Haleon have introduced Ed the chatbot to help target the correct users online, so that correct user segment targeting began a while ago.

Lombard obviously have ideas to discuss with the board about future business model.(Chairman statement?)

Then give Haleon Eroxon Intense by early next year and again they sell in an immediate boost to stock stores, likewise with Coopers.

So follow Haleon results at end of month and their capital markets day 1st May and there will likely be more valuable news in a few minutes than an hour from FUM BOD.

Results reasonable but now back to 'normal' trading pattern slow bleed by small prics.

Thanks for posting slock.well at least they replied (after pressure and kudos to you for pressing the issues) and the statement re the the milestone payment is a small positive.

Response from Alma Strategic on the 2 questions I posed to the company which InvestorMeet repeatedly deleted.....

Q) The January update detailed lower US sales versus expectations. Can you update on current US trading. How have sales performed in Feb/Mar against your revised expectations and also the original pre January expectations

A) I’m afraid we don’t break this information out and therefore can’t share selectively. As explained yesterday, the information by segment is shared retrospectively

Q) If the company does not achieve the required US sales to trigger the milestone payment in FY25, is this payment lost or would it just fall into early FY26? Secondly, what is the expected sales gap to achieve the payment in FY25 as originally forecast (in units / box of 4)

A) On the milestone payments, they aren’t lost, but we cannot confirm what triggers them and can’t disclose anything in relation to timing.

Thanks to slock for adding comments on the Investor Meet. Sorry to see it wasn't more inspiring!

"As is common with the launch of new products in new categories, there is a need to educate the consumer on how to use the product effectively, and the learnings we have taken so far will enable us, and our partners, to have a more targeted approach for the most recent and future launches of Eroxon®. We, and our partners, remain confident in and committed to the successful launches of Eroxon® around the world."

Acknowledgment of poor reviews? For in my view people thinking its going to make it rock hard with no stimulation or partner involved?

The results looked pretty good and I expect these to get back to 40p in no time. Fingers crossed as this investment looked doomed to me weeks back when it just in free fall!

BRV Capricorn

Slock, thanks for Stifel analysis.

As Stifel is the company's joint broker they can hardly come out with a negative review.

It would be helpful of them to say how many years before we can expect to reach a share price of £1.40 but like most brokers forecasts, a timeline is not given.

Said that they now have US manufacturing, so subject to US demand and available capacity, shoud be no impact

What's the impact for fum?

Noticed in the video chat this morning we got it’s a shame about the share price dropping but the slow uptake was to be expected with a new OTC product like Eroxon with the stigma involved?? Well why did the forecasted predictions you were part of not reflect that!! Absolute IDIOTS! That was the reason for the drop the over ambitious forecasts which again you wasted our money on. Anyone notice the increased manufacturing costs 60% versus 40% 2023? How much of that was CMO setup costs or are we saying that with current volumes we lose 60% of sales before admin costs then taxes?

Didn’t get to see the meeting so how did JB behave? Was he carelessly looking out the window again like in previous meetings and looking totally disinterested in his role as CEO?

More like it just demonstrates that people take a blinkered view and herd principles apply.

I know we are coming from a very low base, but to be in positive territory on results day seems significant for FUM. As a reminder, the share price has not reacted well in recent past.....

10Sep24 H1 ↓5%

10Apr24 FY ↓13.5%

18Sep23 H1 ↓4.2%

05Apr23 FY ↓3.1%

13Sep22 H1 ↓4.4%

26Apr22 FY ↑1.4%

I wonder if this could pave the way for HLN to tender for the China license for Eroxon?

15 April 2025: Haleon plc (the "Company" or "Haleon") announces that following the acquisition of a 33% equity interest in Tianjin TSKF Pharmaceutical Co., Ltd. ("TSKF"), its OTC joint venture in China in December 2024, it has today entered into an agreement to acquire the remaining 12% equity interest from its partner Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited ("DRTG"). This transaction is for a total consideration of RMB 1,623 million (c. £0.2 billion) and will result in TSKF becoming a wholly owned subsidiary of Haleon.

Any thoughts on whether Lombard would have vetted the results RNS? On first glance it appears well written.

The stock been sold-off in the past few month. No amount of good news is going turn around soon.

CEO's renumeration alone about 70% of the annual profits and total staff cost is about 6 times the profit. This would take many years to turn around unless cost is tightened. With no marketing roles why the staff cost is so high. All manufacturing been farmed out.

That's the spin. The truth comes later. It isn't as pretty.

I traded these in the 30-45p range, but haven’t looked at them for a long time. I didn’t even think about them until I saw them on the top shelf in a boots branch yesterday. I should always read the signs! I could have bought them much cheaper yesterday!!

I’m happy to buy and hold now.

Financial highlights

·

FY24 revenue and profit after tax ahead of market expectations1, with revenue growth of 349% to £13.9 million (FY23: £3.1 million)

·

Profit after tax of £1.3 million, with the Group maintaining an efficient operating model, as distribution partners take on marketing costs

·

Blended gross margin2 increased to 70% (FY23: 57%) reflecting the revenue mix of product sales, milestones and royalties

·

Cash and cash equivalents of £6.6 million at 31 December 2024 (FY23: £7.7 million), which provides working capital through to H2 2026, along with expected revenues, we remain well capitalised with working capital to support our operations and current focused investment in R&D

Post-period end and outlook

·

Feedback and market research from early launches assist in adjusting and optimising marketing strategies in the period ahead. This, along with some launch delays in markets outside of the US resulted in a slower ramp-up and expansion of retail sales. As previously disclosed, whilst early in the new fiscal year and launch phase, the Board update on the expected impact to FY25 revenue and profit

·

Relationships with distribution partners remain strong as does partner commitment to Eroxon® and the Group continues to work closely with partners ahead of the next phase of launches and rollouts

·

New product development pipeline provides confidence in the successful expansion of our product range and addressable markets

·

On track to have launched Eroxon® in 20 countries by the end of 2025 with manufacturing capacity now in both the EU and US

·

Successful completion and positive results of an Eroxon® Intense Home User study in March 2025 with US and EU approvals remaining on track by the end of 2025

·

Successful completion and positive results of a Home User study on WSD4000, a topical treatment for the symptoms associated with sexual dysfunction in women, in January 2025 and a further pre-submission meeting with the FDA has taken place.